The September 2019 quarter revenue stood at Rs. 8821.00 millions, up 8.06% as compared to Rs. 8163.10 millions during the corresponding quarter last year.The Total revenue for the quarter ended September 2019 of  Rs. 5027.90  millions  grew by 398.95% from Rs. 1007.70 millions.Operating Profit saw a handsome growth to 2098.50 millions from 1799.80 millions in the quarter ended September 2019. (Rs. in Million) Quarter ended Year to Date Year ended 201909 201809 % Var 201909 201809 % Var 201903 201803 % Var Sales 8821.00 8163.10 8.06 16701.20 15519.60 7.61 31285.30 28958.80 8.03 Other Income 156.10 148.20 5.33 461.50 326.00 41.56 1014.80 535.20 89.61 PBIDT 2098.50 1799.80 16.60 4058.70 3381.30 20.03 7079.60 5619.60 25.98 Interest 9.20 2.20 318.18 18.50 4.20 340.48 5.50 1.90 189.47 PBDT 6100.70 1679.70 263.20 8051.60 3176.40 153.48 7123.00 5795.70 22.90 Depreciation 227.00 115.10 97.22 417.60 228.70 82.60 485.90 379.90 27.90 PBT 5873.70 1564.60 275.41 7634.00 2947.70 158.98 6637.10 5415.80 22.55 TAX 845.80 556.90 51.88 1471.50 1054.10 39.60 2383.50 1896.00 25.71 Deferred Tax 193.70 43.10 349.42 255.30 93.30 173.63 455.30 -147.40 -408.89 PAT 5027.90 1007.70 398.95 6162.50 1893.60 225.44 4253.60 3519.80 20.85 Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 847.00 100.01 PBIDTM(%) 23.79 22.05 7.90 24.30 21.79 11.54 22.63 19.41 16.61

The June 2019 quarter revenue stood at Rs. 7880.20 millions, up 7.12% as compared to Rs. 7356.50 millions during the corresponding quarter last year.A comparatively good net profit growth of 28.07% to Rs. 1134.60 millions was reported for the quarter ended June 2019 compared to Rs. 885.90 millions of previous same quarter.Operating Profit saw a handsome growth to 1960.20 millions from 1581.50 millions in the quarter ended June 2019. (Rs. in Million) Quarter ended Year to Date Year ended 201906 201806 % Var 201906 201806 % Var 201903 201803 % Var Sales 7880.20 7356.50 7.12 7880.20 7356.50 7.12 31285.30 28958.80 8.03 Other Income 305.40 177.80 71.77 305.40 177.80 71.77 1014.80 535.20 89.61 PBIDT 1960.20 1581.50 23.95 1960.20 1581.50 23.95 7079.60 5619.60 25.98 Interest 9.30 2.00 365.00 9.30 2.00 365.00 5.50 1.90 189.47 PBDT 1950.90 1496.70 30.35 1950.90 1496.70 30.35 7123.00 5795.70 22.90 Depreciation 190.60 113.60 67.78 190.60 113.60 67.78 485.90 379.90 27.90 PBT 1760.30 1383.10 27.27 1760.30 1383.10 27.27 6637.10 5415.80 22.55 TAX 625.70 497.20 25.84 625.70 497.20 25.84 2383.50 1896.00 25.71 Deferred Tax 61.60 50.20 22.71 61.60 50.20 22.71 455.30 -147.40 -408.89 PAT 1134.60 885.90 28.07 1134.60 885.90 28.07 4253.60 3519.80 20.85 Equity 1694.10 847.00 100.01 1694.10 847.00 100.01 1694.10 847.00 100.01 PBIDTM(%) 24.88 21.50 15.71 24.88 21.50 15.71 22.63 19.41 16.61

Glaxosmithkline Pharmaceuticals is currently trading at Rs. 1232.00, up by 2.15 points or 0.17% from its previous closing of Rs. 1229.85 on the BSE.The scrip opened at Rs. 1229.85 and has touched a high and low of Rs. 1238.90 and Rs. 1225.20 respectively. The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 1812.00 on 11-Sep-2018 and a 52 week low of Rs. 1,225.20 on 24-Jun-2019.Last one week high and low of the scrip stood at Rs. 1259.50 and Rs. 1225.20 respectively. The current market cap of the company is Rs. 20987.71 crore.The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.53% and 12.47% respectively.GlaxoSmithKline Pharmaceuticals is optimising its product portfolio with focus on key brands to accelerate growth in India. The company is also looking to launch some new products in the country over the next 15 months as it adopts a more structured approach to engage trade channel partners, with a dedicated team to engage stockists and retailers across India.GlaxoSmithKline Pharmaceuticals(GSK Rx India) is one of the oldest pharmaceuticals company. The GSK India product portfolio includes prescription medicines and vaccines.

Glaxosmithkline Pharmaceuticals is currently trading at Rs. 1280.00, up by 8.35 points or 0.66% from its previous closing of Rs. 1271.65 on the BSE.The scrip opened at Rs. 1280.00 and has touched a high and low of Rs. 1289.95 and Rs. 1271.00 respectively. So far 2226 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 1812.00 on 11-Sep-2018 and a 52 week low of Rs. 1165.55 on 25-May-2018.Last one week high and low of the scrip stood at Rs. 1292.00 and Rs. 1261.05 respectively. The current market cap of the company is Rs. 21599.27 crore.The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.53% and 12.47% respectively.Glaxosmithkline Pharmaceuticals has reported a rise of 16.56% in its net profit at Rs 123.03 crore for the quarter ended March 31, 2019 as compared to Rs 105.55 crore for the same quarter in the previous year. Total income of the company increased by 4.81% at Rs 803.68 crore for Q4FY19 as compared Rs 766.77 crore for the corresponding quarter previous year.For the year ended March 31, 2019, the company has reported a rise of 20.85% in its net profit at Rs 425.36 crore as compared to Rs 351.98 crore for the previous year. Total income of the company increased by 9.51% at Rs 3,230.01 crore for year under review as compared to Rs 2,949.40 crore for year ended March 31, 2018.For the year ended March 31, 2019, on the consolidated basis, the company has reported a rise of 26.99% in its net profit at Rs 445.39 crore as compared to Rs 350.72 crore for the previous year. Total income of the company increased by 9.50% at Rs 3,230.44 crore for year under review as compared to Rs 2,950.19 crore for year ended March 31, 2018.

The company`s total revenue for the quarter ended March 2019 saw a slight change in the total revenue, having registered a total revenue of Rs. 7512.20 millions.Net profit stood at Rs. 1230.30  millions  compared to Rs. 1055.50 millions in the corresponding previous quarter,high by 16.56%.The company reported a good operating profit of 2160.90 millions compared to 1730.10 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201903 201803 % Var 201903 201803 % Var 201903 201803 % Var Sales 7512.20 7486.20 0.35 31285.30 28958.80 8.03 31285.30 28958.80 8.03 Other Income 524.60 181.50 189.04 1014.80 535.20 89.61 1014.80 535.20 89.61 PBIDT 2160.90 1730.10 24.90 7079.60 5619.60 25.98 7079.60 5619.60 25.98 Interest 0.80 0.40 100.00 5.50 1.90 189.47 5.50 1.90 189.47 PBDT 2128.40 1729.70 23.05 7123.00 5795.70 22.90 7123.00 5795.70 22.90 Depreciation 136.80 93.60 46.15 485.90 379.90 27.90 485.90 379.90 27.90 PBT 1991.60 1636.10 21.73 6637.10 5415.80 22.55 6637.10 5415.80 22.55 TAX 761.30 580.60 31.12 2383.50 1896.00 25.71 2383.50 1896.00 25.71 Deferred Tax 479.80 -141.60 -438.84 455.30 -147.40 -408.89 455.30 -147.40 -408.89 PAT 1230.30 1055.50 16.56 4253.60 3519.80 20.85 4253.60 3519.80 20.85 Equity 1694.10 847.00 100.01 1694.10 847.00 100.01 1694.10 847.00 100.01 PBIDTM(%) 28.77 23.11 24.47 22.63 19.41 16.61 22.63 19.41 16.61

A fair growth of 17.25% in the revenue at Rs. 8253.50 millions was reported in the December 2018 quarter as compared to Rs. 7039.10 millions during year-ago period.An average growth of 25.96% was recorded for the quarter ended December 2018 to Rs. 1129.70  millions from Rs. 896.90 millions.Operating profit for the quarter ended December 2018 decreased to 1537.40 millions as compared to 1538.00 millions of corresponding quarter ended December 2017. (Rs. in Million) Quarter ended Year to Date Year ended 201812 201712 % Var 201812 201712 % Var 201803 201703 % Var Sales 8253.50 7039.10 17.25 23773.10 21472.60 10.71 28958.80 29945.10 -3.29 Other Income 164.20 119.90 36.95 490.20 353.70 38.59 535.20 720.10 -25.68 PBIDT 1537.40 1538.00 -0.04 4918.70 3889.50 26.46 5619.60 4919.50 14.23 Interest 0.50 0.40 25.00 4.70 1.50 213.33 1.90 2.50 -24.00 PBDT 1818.20 1537.60 18.25 4994.60 4066.00 22.84 5795.70 5374.30 7.84 Depreciation 120.40 133.80 -10.01 349.10 286.30 21.94 379.90 263.50 44.17 PBT 1697.80 1403.80 20.94 4645.50 3779.70 22.91 5415.80 5110.80 5.97 TAX 568.10 506.90 12.07 1622.20 1315.40 23.32 1896.00 1743.00 8.78 Deferred Tax -117.80 -23.60 399.15 -24.50 -5.80 322.41 -147.40 113.30 -230.10 PAT 1129.70 896.90 25.96 3023.30 2464.30 22.68 3519.80 3367.80 4.51 Equity 1694.00 847.00 100.00 1694.00 847.00 100.00 847.00 847.00 0.00 PBIDTM(%) 18.63 21.85 -14.75 20.69 18.11 14.22 19.41 16.43 18.12

Revenue reduced marginally to stand at Rs. 8163.10 millions during the quarter ended September 2018. The figure stood at Rs. 8362.60 millions during the year-ago period.Net profit declined -22.67% to Rs. 1007.70 millions from Rs. 1303.20 millions.A decline of 1799.80 millions was observed in the OP in the quarter ended September 2018 from 2017.20 millions on QoQ basis. (Rs. in Million) Quarter ended Year to Date Year ended 201809 201709 % Var 201809 201709 % Var 201803 201703 % Var Sales 8163.10 8362.60 -2.39 15519.60 14433.50 7.52 28958.80 29945.10 -3.29 Other Income 148.20 96.30 53.89 326.00 233.80 39.44 535.20 720.10 -25.68 PBIDT 1799.80 2017.20 -10.78 3381.30 2351.50 43.79 5619.60 4919.50 14.23 Interest 2.20 0.20 1000.00 4.20 1.10 281.82 1.90 2.50 -24.00 PBDT 1679.70 2068.60 -18.80 3176.40 2528.40 25.63 5795.70 5374.30 7.84 Depreciation 115.10 77.30 48.90 228.70 152.50 49.97 379.90 263.50 44.17 PBT 1564.60 1991.30 -21.43 2947.70 2375.90 24.07 5415.80 5110.80 5.97 TAX 556.90 688.10 -19.07 1054.10 808.50 30.38 1896.00 1743.00 8.78 Deferred Tax 43.10 12.70 239.37 93.30 17.80 424.16 -147.40 113.30 -230.10 PAT 1007.70 1303.20 -22.67 1893.60 1567.40 20.81 3519.80 3367.80 4.51 Equity 1694.00 847.00 100.00 1694.00 847.00 100.00 847.00 847.00 0.00 PBIDTM(%) 22.05 24.12 -8.60 21.79 16.29 33.73 19.41 16.43 18.12

The revenue zoomed 21.18% to Rs. 7356.50 millions for the quarter ended June 2018 as compared to Rs. 6070.90 millions during the corresponding quarter last year.The Net Profit of the company reported a remarkable increase of 235.31% to Rs. 885.90  millions  from Rs. 264.20 millions in previous same quarter.Operating Profit saw a handsome growth to 1581.50 millions from 334.30 millions in the quarter ended June 2018. (Rs. in Million) Quarter ended Year to Date Year ended 201806 201706 % Var 201806 201706 % Var 201803 201703 % Var Sales 7356.50 6070.90 21.18 7356.50 6070.90 21.18 28958.80 29945.10 -3.29 Other Income 177.80 137.50 29.31 177.80 137.50 29.31 535.20 720.10 -25.68 PBIDT 1581.50 334.30 373.08 1581.50 334.30 373.08 5619.60 4919.50 14.23 Interest 2.00 0.90 122.22 2.00 0.90 122.22 1.90 2.50 -24.00 PBDT 1496.70 459.80 225.51 1496.70 459.80 225.51 5795.70 5374.30 7.84 Depreciation 113.60 75.20 51.06 113.60 75.20 51.06 379.90 263.50 44.17 PBT 1383.10 384.60 259.62 1383.10 384.60 259.62 5415.80 5110.80 5.97 TAX 497.20 120.40 312.96 497.20 120.40 312.96 1896.00 1743.00 8.78 Deferred Tax 50.20 5.10 884.31 50.20 5.10 884.31 -147.40 113.30 -230.10 PAT 885.90 264.20 235.31 885.90 264.20 235.31 3519.80 3367.80 4.51 Equity 847.00 847.00 0.00 847.00 847.00 0.00 847.00 847.00 0.00 PBIDTM(%) 21.50 5.51 290.40 21.50 5.51 290.40 19.41 16.43 18.12

Glaxosmithkline Pharmaceuticals is currently trading at Rs. 2495.25, up by 72.45 points or 2.99% from its previous closing of Rs. 2422.80 on the BSE.The scrip opened at Rs. 2440.00 and has touched a high and low of Rs. 2538.00 and Rs. 2440.00 respectively. So far 3371 shares were traded on the counter.The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 2999.90 on 28-Oct-2016 and a 52 week low of Rs. 2309.05 on 30-May-2017.Last one week high and low of the scrip stood at Rs. 2538.00 and Rs. 2381.10 respectively. The current market cap of the company is Rs. 21175.75 crore.The promoters holding in the company stood at 75.00%, while institutions and non-institutions held 12.32% and 12.68% respectively.Glaxosmithkline Pharmaceuticals has reported a rise of 31.84% in its net profit at Rs 130.32 crore for the quarter under review as compared to net profit of Rs 98.85 crore for the same quarter in the previous year. Total income of the company increased by 3.51% at Rs 845.87 crore for Q2FY18 as compared Rs 817.20 crore for the corresponding quarter previous year.GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world`s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

The Total revenue for the quarter ended September 2017 of  Rs. 8362.60 millions remain, more or less, the same.A comparatively good net profit growth of 31.84% to Rs. 1303.20 millions was reported for the quarter ended September 2017 compared to Rs. 988.50 millions of previous same quarter.The company reported a good operating profit of 2017.00 millions compared to 1588.20 millions of corresponding previous quarter. (Rs. in Million) Quarter ended Year to Date Year ended 201709 201609 % Var 201709 201609 % Var 201703 201603 % Var Sales 8362.60 7991.20 4.65 14433.50 15044.50 -4.06 29945.10 28262.10 5.95 Other Income 96.10 180.80 -46.85 232.70 421.00 -44.73 717.60 1218.20 -41.09 PBIDT 2017.00 1588.20 27.00 2350.40 2731.90 -13.96 4917.00 5985.80 -17.86 Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PBDT 2068.60 1589.80 30.12 2528.40 2751.70 -8.11 5374.30 6008.90 -10.56 Depreciation 77.30 65.80 17.48 152.50 119.50 27.62 263.50 249.50 5.61 PBT 1991.30 1524.00 30.66 2375.90 2632.20 -9.74 5110.80 5759.40 -11.26 TAX 688.10 535.50 28.50 808.50 921.00 -12.21 1743.00 2014.10 -13.46 Deferred Tax 12.70 -13.00 -197.69 17.80 -3.40 -623.53 0.00 0.00 0.00 PAT 1303.20 988.50 31.84 1567.40 1711.20 -8.40 3367.80 3745.30 -10.08 Equity 847.00 847.00 0.00 847.00 847.00 0.00 847.00 847.00 0.00 PBIDTM(%) 24.12 19.87 21.36 16.28 18.16 -10.32 16.42 21.18 -22.47

GlaxoSmithKline Pharmaceuticals is currently trading at Rs. 2441.50, up by 13.45 points or 0.55% from its previous closing of Rs. 2428.05 on the BSE.The scrip opened at Rs. 2485.00 and has touched a high and low of Rs. 2490.00 and Rs. 2441.00 respectively. The BSE group `A` stock of face value Rs. 10 has touched a 52 week high of Rs. 2999.90 on 28-Oct-2016 and a 52 week low of Rs. 2309.05 on 30-May-2017.Last one week high and low of the scrip stood at Rs. 2490.00 and Rs. 2380.00 respectively. The current market cap of the company is Rs. 20,680.00 crore.The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 12.18% and 12.82% respectively.GlaxoSmithKline Pharmaceuticals has received an approval for sale of its land admeasuring approximately 60 acres located at Thane, Maharashtra to Oberoi Realty for a consideration of Rs 555 crore. The board of directors at its meeting held on September 22, 2017 has approved for the same.The proposed sale of land is subject to receipt of all statutory and regulatory approvals from the concerned authorities and signing of the definitive documents between the company and Oberoi Realty in this regard.GlaxoSmithKline Pharmaceuticals is a subsidiary of GlaxoSmithKline plc, one of the world`s leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human life by enabling people to do more, feel better and live longer.

The sales for the June 2017 quarter moved down to Rs. 6070.90 millions as compared to Rs. 7053.30 millions during the year-ago period.The Company to register a -63.44%  fall in the net profit for the quarter ended June 2017.A decline of 333.40 millions was observed in the OP in the quarter ended June 2017 from 1143.70 millions on QoQ basis. (Rs. in Million) Quarter ended Year to Date Year ended 201706 201606 % Var 201706 201606 % Var 201703 201603 % Var Sales 6070.90 7053.30 -13.93 6070.90 7053.30 -13.93 29945.10 28262.10 5.95 Other Income 136.60 240.20 -43.13 136.60 240.20 -43.13 717.60 1218.20 -41.09 PBIDT 333.40 1143.70 -70.85 333.40 1143.70 -70.85 4917.00 5985.80 -17.86 Interest 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 PBDT 459.80 1161.90 -60.43 459.80 1161.90 -60.43 5374.30 6008.90 -10.56 Depreciation 75.20 53.70 40.04 75.20 53.70 40.04 263.50 249.50 5.61 PBT 384.60 1108.20 -65.30 384.60 1108.20 -65.30 5110.80 5759.40 -11.26 TAX 120.40 385.50 -68.77 120.40 385.50 -68.77 1743.00 2014.10 -13.46 Deferred Tax 5.10 9.60 -46.88 5.10 9.60 -46.88 0.00 0.00 0.00 PAT 264.20 722.70 -63.44 264.20 722.70 -63.44 3367.80 3745.30 -10.08 Equity 847.00 847.00 0.00 847.00 847.00 0.00 847.00 847.00 0.00 PBIDTM(%) 5.49 16.22 -66.13 5.49 16.22 -66.13 16.42 21.18 -22.47